Psoriasis
Despite a Slight Increase in the Use of Biologic Agents to Treat Psoriasis in the Past Year, Dermatologists in the EU Are Not Expected to Drastically Change Their Future Prescribing Habits
Published in Pharma Business Week, April 30th, 2012
2012 APR 30 -- In a recent TreatmentTrends© study with EU5 dermatologists, BioTrends Research Group, LLC finds that there has been a slight increase in the use of biologics in all of the EU5 countries except Italy, where usage has remained constant. Future prescribing habits will see moderate increases in prescribing for both Janssen's Stelara and Abbott's Humira, but this increase will be at the expense of Amgen's Enbrel and other biologic agents.
Depending on the severity of their psoriasis, patients with a mild case are treated with a single pharmacological therapy and those patients suffering from moderate to severe are often treated with multiple...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
Source: Pharma Business Week (2012-04-30)
More Articles from Pharma Business Week
- Adventrx Pharmaceuticals, Inc.
ADVENTRX Pharmaceuticals to Sponsor & Present at the Martin Center's 2012 Sickle Cell Disease Conference - Research and Markets
Colombia Pharmaceuticals and Healthcare Report Q2 2012 - Pharmaceutical Companies
Iroko Pharmaceuticals Makes Strategic Additions to Executive Team with Appointment of Clarence L. Young, M.D. as Chief Medical Officer and Moji James as General Counsel - Prix Galien Usa
The Galien Foundation Announces Prix Galien USA Awards Committee, Chaired by Dr. P. Roy Vagelos - Biotechnology
Alnylam to Webcast Presentation at Future Leaders in the Biotech Industry Conference - Hepatitis C Virus
Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients - More from this issue of Pharma Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
